EP3755312A4 - DOSAGE FORMS AND PROCESSES FOR ENANTIOMER ENHANCED OR PURE BUPROPION - Google Patents
DOSAGE FORMS AND PROCESSES FOR ENANTIOMER ENHANCED OR PURE BUPROPION Download PDFInfo
- Publication number
- EP3755312A4 EP3755312A4 EP19756920.5A EP19756920A EP3755312A4 EP 3755312 A4 EP3755312 A4 EP 3755312A4 EP 19756920 A EP19756920 A EP 19756920A EP 3755312 A4 EP3755312 A4 EP 3755312A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- dosage forms
- enantiomerically enriched
- pure bupropion
- obtaining enantiomerically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US201962809480P | 2019-02-22 | 2019-02-22 | |
| PCT/US2019/019445 WO2019165379A1 (en) | 2018-02-23 | 2019-02-25 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3755312A1 EP3755312A1 (en) | 2020-12-30 |
| EP3755312A4 true EP3755312A4 (en) | 2022-03-16 |
Family
ID=67688503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19756920.5A Pending EP3755312A4 (en) | 2018-02-23 | 2019-02-25 | DOSAGE FORMS AND PROCESSES FOR ENANTIOMER ENHANCED OR PURE BUPROPION |
Country Status (19)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3092076A1 (en) * | 2018-02-23 | 2019-08-29 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| CN114423417A (zh) * | 2019-09-20 | 2022-04-29 | 艾克萨姆治疗公司 | 用于对映体富集的或纯的安非他酮的剂型和方法 |
| US20250073188A1 (en) | 2020-06-05 | 2025-03-06 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US12036191B1 (en) | 2022-06-30 | 2024-07-16 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US12156914B2 (en) | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| KR20250114110A (ko) | 2022-11-28 | 2025-07-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 약물 활성의 조절제로서의 부프로피온 |
| WO2025259728A1 (en) * | 2024-06-13 | 2025-12-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013014166A (es) * | 2013-12-03 | 2015-06-10 | Inst De Investigacion En Quimica Aplic S A De C V | Enantiomeros activos y sus sales para el tratamiento de la obesidad. |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999038502A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| CN1819821B (zh) * | 2003-08-08 | 2010-10-13 | 拜奥维尔实验室国际股份有限公司 | 盐酸安非他酮的改良释放片剂 |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| EP3981403A1 (en) * | 2013-11-05 | 2022-04-13 | Antecip Bioventures II LLC | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9732031B2 (en) * | 2013-12-20 | 2017-08-15 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| CA3092076A1 (en) * | 2018-02-23 | 2019-08-29 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
-
2019
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/zh active Pending
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/es unknown
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
- 2019-02-25 MA MA051914A patent/MA51914A/fr unknown
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 IL IL276871A patent/IL276871B2/en unknown
- 2019-02-25 KR KR1020247017593A patent/KR20240091043A/ko not_active Ceased
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en not_active Ceased
- 2019-02-25 CR CR20200415A patent/CR20200415A/es unknown
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/ja active Pending
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/ko not_active Ceased
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/pt not_active Application Discontinuation
- 2019-02-25 CN CN202510967625.3A patent/CN120827545A/zh active Pending
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/ko not_active Ceased
- 2019-02-25 MY MYPI2020004315A patent/MY202993A/en unknown
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 IL IL313368A patent/IL313368A/en unknown
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/es unknown
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/es unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/es unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/es unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/es unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521B2/en active Active
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/ja active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/ja active Pending
- 2024-08-17 AU AU2024205858A patent/AU2024205858A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| MX2013014166A (es) * | 2013-12-03 | 2015-06-10 | Inst De Investigacion En Quimica Aplic S A De C V | Enantiomeros activos y sus sales para el tratamiento de la obesidad. |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2019165379A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3092076A1 (en) | 2019-08-29 |
| PE20211752A1 (es) | 2021-09-06 |
| CN120827545A (zh) | 2025-10-24 |
| AU2019223187A1 (en) | 2020-09-17 |
| NI202000056A (es) | 2021-01-11 |
| IL276871A (en) | 2020-10-29 |
| JP2021513998A (ja) | 2021-06-03 |
| MY202993A (en) | 2024-05-31 |
| KR20240091043A (ko) | 2024-06-21 |
| IL276871B2 (en) | 2024-11-01 |
| MX2020008704A (es) | 2020-12-07 |
| AU2024205858A1 (en) | 2024-09-05 |
| IL313368A (en) | 2024-08-01 |
| WO2019165379A1 (en) | 2019-08-29 |
| ECSP20060179A (es) | 2020-12-31 |
| CN112087999A (zh) | 2020-12-15 |
| MX2023009281A (es) | 2023-08-17 |
| EP3755312A1 (en) | 2020-12-30 |
| BR112020017179A2 (pt) | 2020-12-22 |
| KR20230075531A (ko) | 2023-05-31 |
| AU2022204521A1 (en) | 2022-07-21 |
| CL2020002166A1 (es) | 2020-10-23 |
| AU2022204521B2 (en) | 2024-09-05 |
| NZ767378A (en) | 2024-03-22 |
| JP2024075655A (ja) | 2024-06-04 |
| AU2019223187B2 (en) | 2022-07-28 |
| CR20200415A (es) | 2021-02-03 |
| MA51914A (fr) | 2020-12-30 |
| SG11202008056SA (en) | 2020-09-29 |
| IL276871B1 (en) | 2024-07-01 |
| KR20210003091A (ko) | 2021-01-11 |
| JP2022153638A (ja) | 2022-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51914A (fr) | Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur | |
| EP3847818A4 (en) | A VIDEO ENCODER, A VIDEO DECODER, AND CORRESPONDING METHODS | |
| EP3987794A4 (en) | ENCODER, DECODER AND METHOD THEREOF | |
| EP3861743A4 (en) | VIDEO DECODER AND METHOD | |
| MA71705A (fr) | Substances et procédés pour le traitement d'hémoglobinopathies | |
| EP3633676A4 (en) | RNN-BASED NOISE REDUCTION METHOD AND DEVICE FOR REAL-TIME CONFERENCE | |
| MA50849A (fr) | Substances et procédés pour le traitement d'hémoglobinopathies | |
| EP3710422C0 (en) | PROCESS FOR PREPARING ENANTIOMERICALLY AND DIASTEROMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES | |
| EP3341391A4 (en) | COMPOSITIONS AND METHODS OF PAIN TREATMENT | |
| EP4070549A4 (en) | ENCODER, DECODER AND RELATED METHODS AND DEVICE | |
| EP3975717C0 (en) | WATER TREATMENT PROCESS AND COMPOSITION | |
| EP3556222C0 (en) | SYSTEM AND METHOD FOR PRODUCING A SUGAR STREAM | |
| EP3478753C0 (en) | CELLULOSE-BASED FILM STRUCTURE AND ITS PRODUCTION PROCESS | |
| EP3552834C0 (en) | WRAP PLATE AND ITS MANUFACTURING PROCESS | |
| EP3864715A4 (en) | DISPLAY SUBSTRATE, DISPLAY APPARATUS AND METHOD OF MAKING DISPLAY SUBSTRATE | |
| EP3982633A4 (en) | VIDEO ENCODER, VIDEO DECODER AND CORRESPONDING METHOD | |
| EP3532042A4 (en) | METHOD FOR IMPROVING SYNAPTOGENESIS AND NEURITOGENESIS | |
| EP4026337A4 (en) | ENCODER, DECODER AND METHOD THEREOF | |
| EP3868110A4 (en) | CODERS, DECODERS AND RELATED METHODS FOR UNBLOCKING FILTER ADAPTATION | |
| EP3461088A4 (en) | Method and apparatus for determining video quality, and method and apparatus for locating network fault | |
| EP4070551A4 (en) | ENCODER, DECODER AND METHOD THEREOF | |
| EP3896974A4 (en) | VIDEO ENCODER, VIDEO DECODER AND METHOD THEREOF | |
| EP3960868A4 (en) | Polyhydroxyalkanoic acid and method for producing same | |
| EP3527191A4 (en) | COMPOSITE DENTAL RESIN MATERIAL, METHOD FOR PRODUCING COMPOSITE DENTAL RESIN MATERIAL, AND POLYARYLETHERCETONE RESIN FOR PRODUCING COMPOSITE DENTAL RESIN MATERIAL | |
| EP3781137A4 (en) | HUMIDITY RESISTANT PROBIOTIC GRANULE AND ITS PRODUCTION PROCESSES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20200921 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TABUTEAU, HERRIOT |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40041795 Country of ref document: HK |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20220216 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 45/06 20060101ALI20220210BHEP Ipc: A61P 25/30 20060101ALI20220210BHEP Ipc: A61P 25/28 20060101ALI20220210BHEP Ipc: A61P 25/24 20060101ALI20220210BHEP Ipc: A61P 25/18 20060101ALI20220210BHEP Ipc: A61P 25/00 20060101ALI20220210BHEP Ipc: A61K 31/485 20060101ALI20220210BHEP Ipc: A61K 31/137 20060101AFI20220210BHEP |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230306 |
|
| RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AXSOME THERAPEUTICS, INC. |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20241014 |